Since its establishment in 2013, PBI has been active in delivering research papers and oral presentations to the scientific and medical community. PBI has been invited to deliver diverse presentations and act as session chair at conferences and meetings; and has been successful in securing a significant number of awards. Additionally, PBI has been recognised for our high scoring and accepted abstracts, a significant achievement for an emerging research institute. 

Research Papers


Baker, R.I., Gilmore, G., Chen, V., et al. Direct oral anticoagulants or Vitamin K antagonists in emergencies: comparison of management in an observational studyResearch and Practice in Thrombosis and Haemostasis (2023), doi:


Capra, M., Martin, T., Moreau, P., Baker, R. Pour, L., Min, C., Leleu, X., Mohty, M., Reinoso Segura, M., Turgut, M., Leblanc, R., Risse, M.,  Malinge, L., Schwab, S., Dimopoulos, M.A. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: Ikema Subgroup AnalysisHaematologica. 2022 Jun 1;107(6):1397-1409. doi: 10.3324/haematol.2021.279229.

Elaskalani, O., Gilmore, G., Hagger, M., Baker, R.I., and Metharom, P. Adenosine 2A receptor activation amplifies ibrutinib antiplatelet effect; implications in chronic lymphocytic leukemia. Cancers (Basel). Nov 2022;14(23):5750. doi: 10.3390/cancers14235750.

Fogarty, H., Ward, S.E., ..... Baker, R.I., Cheallaigh, C.N., O'Donnell, J.S. Sustained VWF‐ADAMTS‐13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunctionJ Thromb Haemost. 2022 Oct;20(10):2429-2438. doi: 10.1111/jth.15830.

Dimopoulos, M.A., Voorhees, P.M., Goldschmidt, H., Baker, R.I., Shi, Y., Rousseau, E., Dennis, R.M., Carson, R.L., Rajkumar, S.V. Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): Randomized, open-label, phase 3 AQUILA studyJournal of Clinical Oncology 40.16_suppl (2022): TPS8075–TPS8075. Web.

Kuter, D.J., Efraim, J., ..... Baker R., et al. Rilzabrutinib, an Oral BTK Inhibitor, in Immune ThrombocytopeniaN Engl J Med. 2022; 386:1421-1431. DOI: 10.1056/NEJMoa2110297

Lavin, M., Sánchez Luceros, A., Kouides, P., Abdul-Kadir, R., O’Donnell, J.S., Baker, R.I., Othman, M., Haberichter, S.L. Examining international practices in the management of pregnant women with von Willebrand disease. J Thromb Haemost. 2022;20:82–91

Kalot, M.A., Husainat, N., El Alayli, A., Abughanimeh, O., Diab, O., Tayiem, S., Madoukh, B., Dimassi, A.B., Qureini, A., Ameer, B., Eikenboom, J.C.J., Giraud, N., McLintock, C., McRae, S. et al. von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis. Blood Advances 2022; 6(1): 62-71. DOI 10.1182/bloodadvances.2021005430.

Lim, M.S., Hayes, R., Sharma, A., Kitiponchai, T., Mohamed, M., & McRae, S. Prospective cohort study on the use of low molecular weight heparin calibrated anti-Xa assay for measurement of direct oral Xa inhibitors in ex vivo patient samples. Pathology 2022; 54(5): 599-605. DOI:10.1016/j.pathol.2022.01.00

Hart, D.P., Matino, D., Astermark, J., Dolan, G., d’Oiron, R., Hermans, C., Jiménez-Yuste, V., Linares, A., Matsushita, T., McRae, S., Ozelo, M.C., Platton, S., Stafford, D., Sidonio Jr. R.F., & Tiede, A. International consensus recommendations on the management of people with haemophilia B. Therapeutic advances in hematology 2022; 13: 1–22. DOI: 10.1177/ 20406207221085202


Baker, R.I. & O'Donnell, J.S. How I treat bleeding disorder of unknown cause. Blood. 2021 Nov; 138(19): 1795-1804.

Kuter. D.J., Tzvetkov, N., Efraim, M., Kaplan, Z., Mayer, J., Choi, P., Jansen, A.J.G., McDonald, V., Baker, R. et al. Updated phase I/II safety and efficacy results for oral bruton tyrosine kinase inhibitor rilzabrutinib in patients with relapsed/refractory immune thrombocytopenia. Blood. 2021 Nov; 138(Supplement 1):14-14. DOI:10.1182/blood-2021-145128.

Wines, B.D., Trist, H.M., Esparon, S., Impey, R.E., Mackay, G.A., Andrews, R.K., Soares da Costa, T.P., Pietersz, G.A., Baker, R.I., and Hogarth, P.M. Fc binding by FcγRIIa is essential for cellular activation by the anti-FcγRIIa mAbs 8.26 and 8.2. Front. Immunol. 12:666813.
doi: 10.3389/fimmu.2021.666813

Fogarty H, Townsend L, Morrin H, Ahmad A, Comerford C, Karampini E, Englert H, Byrne M, Bergin C, O’Sullivan JM, Martin-Loeches I, Nadarajan P, Bannan C, Mallon PW, Curley GF, Preston RJS, Rehill AM, McGonagle D, Cheallaigh CN, Baker RI, Renné T, Ward SE, O’Donnell JS, the Irish COVID-19 Vasculopathy Study (iCVS) investigators. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost 2021 Oct; 19(10): 2546-2553.

Ward SE, Fogarty H, Karampini E, Lavin M, Schneppenheim S, Dittmer R, Morrin H, Glavey S, Cheallaigh CN, Bergin C, Martin-Loeches I, Mallon PW, Curley GF, Baker RI, Budde U, O’Sullivan JM, O’Donnell JS, the Irish COVID-19 Vasculopathy Study (iCVS) investigators. ADAMTS13 regulation of VWF multimer distribution in severe COVID-19. J Thromb Haemost 2021 Aug; 19(8): 1914-1921.

Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min C, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 2021 June; 397(10292): 2361-2371.

Matasar MJ, Capra M, Özcan M, Lv F, Li W, Yañez E, Sapunarova K, Lin T, Jin J, Jurczak W, Hamed A, Wang M, Baker R, Bondarenko I, Zhang Q, Feng J, Geissler K, Lazaroiu M, Saydam G, Szomor Á, Bouabdallah K, Galiulin R, Uchida T, Mongay Soler L, Cao A, Hiemeyer F, Mehra A, Childs BH, Shi Y, Zinzani PL. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology 2021 May; 22(5): 678–89.

Tian J, Adams MJ, Tay J.W.T, James I, Powell S, Hughes QW, Gilmore GBaker RI, Tiao JY-HEstradiol-responsive miR-365a-3p interacts with tissue factor 3′UTR to modulate tissue factor-initiated thrombin generation. Thromb Haemost 2021 Feb (online).

Lim, M.S., & Mcrae, S. COVID-19 and immunothrombosis: Pathophysiology and therapeutic implications. Critical Reviews in Oncology/Hematology 2021; 168.

James, P.D., Connell, N.T., Ameer, B., Di Paola, J., Eikenboom, J., Giraud, N., Haberichter, S., Jacobs-Pratt, V., Konkle, B., McLintock, C., McRae, S. et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Advances 2021; 5 (1): 280-300. DOI 10.1182/bloodadvances.2020003265.


Mackie I, Mancini I, Muia J, Kremer Hovinga J, Nair S, Machin S, Baker R. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13. Int J Lab Hemat 2020 Dec: 42(6): 685-696.

Nagler MHendriks T, McGregor S, Rakesh S, Robinson J, Ho KM, Baker RPatient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism – The Swan Study. PLoS ONE 2020 Jun; 15(6): e0234048.

Favaloro EJ, Gilmore G, Bonar RDean E, Arunachalam S, Mohammed S, Baker R. Reducing the effect of DOAC interference in laboratory testing for factor VIII and factor IX: A comparative study using DOAC Stop and andexanet alfa to neutralize rivaroxaban effects. Haemophilia 2020 March; 26(2): 354-362.

Favaloro EJGilmore GBonar R, Dean E, Arunachalam S, Mohammed S, Baker R. Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interferenceClinical Chemistry and Laboratory Medicine 2020; 58(8).

Tiao J, Powell S, Gilmore G, Veedu R, Wilton S, Baker R. Splice inducing Antisense Oligonucleotides as a potential gene correction therapy for haemophilia A. Haemophilia 2020; 26(S4): 21-22.

Brennan, Y., Parikh, S., McRae, S., & Tran, H. The Australian experience with switching to extended half‐life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation. Haemophilia 2020; 26:529–535.


Ho KM, Rao S, Honeybul S, Zellweger R, Wibrow B, Lipman J, Holley A, Kop A, Geelhoed E, Corcoran T, Misur P, Edibam C, Baker RI, Chamberlain J, et al. A Multicenter Trial of Vena Cava Filters in Severely Injured Patients. N Engl J Med. 2019 Jul 25; 381(4):328-337.

Oh JOh D, Lee SJ, Kim JH, Kim NK, Chong SY, Huh JY, Baker RI. Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura. Blood Research 2019; 54(3): 218-228.

Favaloro EJ, Gilmore G, Arunachalam S, Mohammed S, Baker RI. Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa. Thromb Res. 2019 Aug; 180:10-19.


Wines BD, Tan CW, Duncan E, McRae S, Baker RI, Andrews RK, et al. Dimeric FcγR ectodomains detect pathogenic anti-platelet factor 4-heparin antibodies in heparin-induced thromobocytopenia. J Thromb Haemost. 2018 Dec; 16 (12):2520-2525.


Hughes QW, Le BT, Gilmore G, Baker RI, Veedu RN. Construction of a Bivalent Thrombin Binding Aptamer and its Antidote with Improved Properties. Molecules. 2017 Oct 19; 22 (10). pii: E1770.

Tay JW, James I, Hughes QW, Tiao JY, Baker RI. Identification of reference miRNAs in plasma useful for the study of oestrogen-responsive miRNAs associated with acquired Protein S deficiency in pregnancy. BMC Res Notes. 2017 Jul 25; 10(1):312.

Tay JW, Tiao J, Hughes Q, Jorritsma J, Gilmore G, Baker R. Circulating microRNA as thrombosis sentinels: Caveats and considerations. Seminars in Thrombosis and Hemostasis. 2017.

Pasi KJ, Fischer K, Ragni M, Nolan B, Perry DJ, Kulkarni R, Ozelo M, Mahlangu J, Shapiro AD, Baker RI, Bennett CM, et al.  Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thromb Haemost. 2017 Feb 28; 117(3):508-518.

Quon DV, Klamroth R, Kulkarni R, Shapiro AD, Baker RI, Castaman G, et al. Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies. Haemophilia. 2017 Jan; 23(1): e39-e42.


Tay, JW, Tiao, J, Hughes, Q, Gilmore, G and Baker, R (2016) Therapeutic Potential of miR-494 in Thrombosis and Other Diseases: A Review. Australian Journal of Chemistry 2016 Jan; 69 (10)

Mahlangu J, Kuliczkowski K, Karim FA, Stasyshyn O, Kosinova MV, Lepatan LM, Skotnicki A, Boggio LN, Klamroth R, Oldenburg J, Hellmann A, Santagostino E, Baker RI, Fischer K, et al; AFFINITY Investigators. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood. 2016 Aug 4; 128 (5):630-7.


Qiao J, Al-Tamimi M, Baker RI, Andrews RK, et al. The platelet Fc receptor, FcγRIIa. Immunol Rev. 2015 Nov; 268(1):241-52.

Metharom P, Berndt MC, Baker RI, Andrews RK. Current state and novel approaches of antiplatelet therapy. Arterioscler Thromb Vasc Biol. 2015 Jun; 35(6):1327-38.


Baker RI, McGregor SR. Does preoperative laboratory monitoring of antithrombotic therapy avoid adverse outcomes in patients undergoing surgery or regional anaesthesia? Anaesth Intensive Care. 2014 Sep; 42(5):555-7.


Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, Josephson NC, Perry D, Manco-Johnson MJ, Apte S, Baker RI, Chan GC, et al; B-LONG Investigators. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013 Dec 12;369 (24):2313-23.

Tay JW, Romeo G, Hughes QW, Baker RI. Micro-ribonucleic Acid 494 regulation of protein S expression. J Thromb Haemost. 2013 Aug; 11(8):1547-55.

Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013 May; 161(3):411-23.



Mr Omar Elaskalani was awarded the prestigious THANZ Scientific Medal for best abstract at the Annual Scientific Meeting - Blood 2019.


Professor Ross Baker, together with a team of researchers, including The Australian National University (ANU), was awarded a four-year NHMRC Project Grant entitled “Pathobiology that causes fatal thrombosis in HIT” starting in 2018. 

In 2018 Dr. Jim Tiao and Professor Ross Baker, and alumni member Dr. Quintin Hughes, were the recipients of grant funding from the John Lloyd Clinical Excellence Fund, for a project to investigate novel gene therapeutics in the treatment of Haemophilia A.

For our work on Haemophilia A, Dr. Jim Tiao was a recipient of the AHCDO Grant in 2018 for his abstract presented at the Annual Scientific Meeting - Blood 2018.


Researchers have also been successful in winning conference presentation awards.  In 2017, PhD candidate Ms Jiayin Tian received a 2017 runner-up prize in the THANZ Scientific Medal conference session.  Ms Tian also received several travel awards for conference presentations, including THANZ scientific and education trust travel grant, Werfen Travel grant and the Murdoch University graduate research conference travel grant.  In 2017, Mr. Michael Menezes was a recipient of best poster prize – scientific, at the same conference. 

In 2017 Dr. Jim Tiao and Professor Ross Baker, and alumni member Dr. Quintin Hughes, were the recipients of grant funding from the John Lloyd Clinical Excellence Fund, for a project to investigate novel gene therapeutics in the treatment of Haemophilia A.


In 2016 researcher Dr Jasmine Tay (alumni) was awarded the inaugural THANZ Scientific Medal for best abstract at the Annual Scientific Meeting – HAA 2016.

In 2016 Dr. Jim Tiao and Professor Ross Baker, and alumni member Dr. Quintin Hughes, were the recipients of grant funding from the John Lloyd Clinical Excellence Fund, for a project to investigate novel gene therapeutics in the treatment of Haemophilia A.